Scientific Program Table

Note: The programme below is accurate as of August 2019 and is subject to change.

Time Monday | 28 October 2019 | UNESCO, Paris
0900 - 1200 Closed Door GG2020 Meeting (By invitation only)
1200 - 1400 Closed Door Meeting - ClinGen
1415 - 1445 Plenary 1
GG2020: Past, present and future (Zilfalil Alwi)(Malaysia)
Country Update
1445 - 1705 TBA
1445 - 1455 Ramdan Panigoro (Indonesia)
1455 - 1505 TBA
1505 - 1515 TBA
1515 - 1525 Celeste Bento (Portugal)
1525 - 1535 Talk 1 – Hamoglobinopathies: Oxidative Stress as Potential Therapeutic Targets (Dr Ruby IPPT)
1535 - 1545 Talk 2 – Prof Azma
TEA BREAK
1545 - 1555 Nasrin Moazami (Iran)
1555 - 1605 TBA
1605 - 1615 Humayun Iqbal Khan (Pakistan)
1615 - 1625 Hafizur Rahman (Bangladesh)
1625 - 1635 Ming Qi (China)
1635 - 1645 Talk 3 (Dr Norafiza)
1645 - 1655 Talk 4 (Dr Veena)
1655 - 1705 End
Time Tuesday | 29 October 2019 | UNESCO, Paris
0900 – 0930 Plenary 2:
Overview of thalassaemia: Milestones and beyond – John Porter (UK)
Symposium 1:
Haemoglobin: Fundamentals and Diagnosis
0930 – 0950 Interaction between unstable haemoglobins and thalassaemias (Henri Wacjman)
0950 – 1010 Genetic Modifiers of Sickle Cell Anaemia in Patients from Nigeria (Rosemary Ekong)
1010 - 1030 Diagnostic strategies in a developing country - Yetty Hernaningsih (Indonesia)
1030 - 1050 Scientific advances in diagnosis - Jacques Elion (France)
1050 - 1110 NGS-based diagnosis (Domenico Coviello)
1110 - 1125 COFFEE BREAK
1125 - 1200 Opening Ceremony
1200 - 1245 Key Note:
Gene Therapy: Success and Challenges

Phillipe LeBoulch(France)
Symposium 2:
Enhancing partnership in patient care
1245 - 1300 Role of support group in empowering patients (Angelo Lores Brunetta)
1300 - 1315 Role of policy makers in ensuring access to achieve patient and family quality of life (Dato’ Dr Narimah Awin)
1315 - 1330 Role of clinicians in ensuring quality health care (Antonio Piga)
1330 – 1415 LUNCH
1415 – 1445 Plenary 3:
EurobloodNet: A European Reference Network for Rare Blood Diseases and a Model for Emulation (Maria del Mar Mañú Pereira)
Symposium 3:
Challenges and burden to the healthcare system
1445 – 1500 The Global Variome Partnership with UNESCO: Challenges and Opportunities (Julia Hassler)
1500 – 1515 Perspective from Thailand (Suthat Fucharoen)
1515 - 1530 Perspective from Europe (Patricia Aguilar Martinez)
1530 – 1545 Perspective from Egypt (Ghada El-Kamah)
1545 – 1600 Perspective from China (Chen Ping)
1600 – 1615 COFFEE BREAK
Free Oral Paper 1
1615 – 1715 Total of 6 (10 minutes each)
Time Wednesday | 30 October 2019 | UNESCO, Paris
Free Oral Paper 2
0900 - 1000 Total of 6 (10 minutes each)
1000 - 1030 Plenary 4:
Genetic modifiers in thalassaemia: Vip Viprakasit
1030 - 1045 COFFEE BREAK
Symposium 4:
Haemoglobin Variant Curation and Interpretation
1045 - 1100 Variant Curation: Overview and Challenges (Coralea Stephanou)
1100 - 1115 Variant Scoring Based on ClinGen Tools and Haemoglobinopathy-specific Criteria (Celeste Bento)
1115 - 1130 The ITHANET-HVP Project: Moving Functional Annotation Forward (Petros Kountouris)
1130 – 1145 COFFEE BREAK
Symposium 5:
Emerging therapy and novel strategies
1145 - 1205 Luspatercept – New kid on the block (Antonio Piga)
1205 - 1220 Point of Care Diagnostics: Are we ready (John Burn)
1220 - 1240 Time of transition: Gene therapy marketing approval and its implications” (Carsten Lederer)
1240 – 1300 Sponsored Lunch Talk
1300 – 1400 LUNCH
Symposium 6:
Screening and Prevention
1415 – 1440 Screening and Prevention of thalassaemia in Cyprus (Marina Kleanthous)
1440 – 1505 Prevention and Control Programme – The Malaysian experience (Dr Saidatul Buang)
1505 - 1530 Ethical Issues in Genetic Counselling for Thalassaemia (Zarina A Latiff)
1530 - 1555 Ethics in Gene Therapy for Thalassaemia (Herve Chneiweiss, Inserm Ethics Committee)
1555 - 1620 olecular Approach for Prenatal Diagnosis in Thalassaemia (Serge Pissard)
1620- 1640 Best Oral Paper/Poster Awards & Closing Remarks
1640 - 1700 COFFEE